CHICAGO, Nov. 14, 2010 /PRNewswire-FirstCall/ — Pfizer Inc.
(NYSE:
PFE) today announced results from the EMPHASIS-HF trial(1)
showing a statistically significant reduction in risk of
cardiovascular (CV) death or heart failure (HF) hospitalization for
patients with chronic heart failure with mild symptoms treated with
Inspra® (eplerenone) versus those given placebo in
addition to standard HF therapy. The results were presented
to physicians attending the American Heart Association Scientific
Sessions in Chicago and were simultaneously published online in the
New England Journal of Medicine.
(Logo:
http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)
(Logo:
http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)
The EMPHASIS-HF trial demonstrated a statistically significant
37% relative risk reduction for the eplerenone group (p<0.0001)
compared to placebo in the primary composite endpoint of death from
CV causes or HF hospitalization. There were also
statistically significant reductions in other secondary endpoints
of all-cause mortality (24%; p=0.008), CV mortality (24%; p=0.012),
all-cause hospitalization (23%, p<0.0001) and HF hospitalization
(42%; p<0.0001).
Heart failure can lead to a reduction in the quality of life,
frequent admissions to hospital and a greatly shortened life
expectancy, despite the availability of several effective
treatments(2). Dr. Faiez Zannad, Professor of Therapeutics
and cardiologist at the CHU (University Hospital) of the Henri
Poincare University of Nancy, France and co-chair of the
EMPHASIS-HF Steering Committee said: “It is encouraging to see a
clinical trial deliver results that are sufficiently strong to meet
strict pre-defined stopping criteria. Patients such as those
enrolled in EMPHASIS-HF typically have a poor prognosis and today’s
results should therefo
‘/>”/>
SOURCE
